Can levetiracetam improve clinical symptoms in schizophrenic patients? A randomized placebo-controlled clinical trial

This study aimed to assess the effect of levetiracetam on the severity of schizophrenia symptoms and cognitive deficits in these patients. Materials and Methods In this randomized, controlled, three-blind randomized clinical trial approved by Mashhad University of Medical Sciences, Iran (IRCT20101130005280N31), forty chronic schizophrenic patients aged 18–60 years were randomly divided into two groups of levetiracetam and placebo. The levetiracetam group received levetiracetam for 8 weeks. The symptoms were evaluated by Positive and Negative Symptoms Scale (PANSS), Stroop test, Digit Span test and Wisconsin Test at baseline, 4th week, and 8th week. Data were analyzed through SPSS V. 23 software, descriptive tests and inferential statistics. Results At the end of the study, all subscales of the PANSS questionnaire reduced significantly (P
Source: International Clinical Psychopharmacology - Category: Psychiatry Tags: Original Articles Source Type: research